LivaNova PLC
LIVN: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| !T | LOCK|^?&yD | LOCK|#? |
LivaNova Earnings: Steady Progress on Execution Is Paying Off
LivaNova's third quarter included top-line growth of 10% in constant currency and adjusted operating income up 15% year over year. Management raised the full-year outlook for both cardiopulmonary and neuromodulation growth by 100 basis points at the midpoint, for total sales growth of 9% to 10%.
